What Research Shows About GLP-1 Drugs as Add-Ons to Insulin for Type 1 Diabetes

Glucagon-like peptide-1 receptor agonists, commonly called GLP-1 drugs, are medications originally developed for Type 2 diabetes. In recent years, researchers have begun investigating whether these drugs might help people with Type 1 diabetes when used alongside insulin therapy. The potential appeal is understandable: GLP-1 drugs work through different mechanisms than insulin and might offer additional benefits such as improved blood sugar control or reduced insulin requirements.

However, determining what the evidence actually shows requires careful analysis of all available research. A team of researchers conducted what's called an 'umbrella review'—a systematic assessment of existing systematic reviews and meta-analyses—to evaluate what we know about GLP-1 drugs as add-on therapy in Type 1 diabetes.

The researchers searched multiple medical databases for systematic reviews and meta-analyses that included randomized controlled trials (the gold standard of research) and other types of studies examining GLP-1 drugs alongside insulin in Type 1 diabetes. They ultimately identified 18 systematic reviews that collectively covered 56 unique primary studies—35 of which were randomized controlled trials.

An important finding emerged during this process: there was substantial overlap between the studies. In other words, the same patient data was being reused and analyzed multiple times across different papers. This overlap means that what appears to be diverse evidence from many independent sources actually relies on a smaller foundation of unique research. This matters because it can make findings seem more robust than they actually are.

The review found inconsistent results across studies, with variable methodological quality and varying degrees of certainty in the evidence. Some studies suggested potential benefits from adding GLP-1 drugs to insulin therapy, while others showed less clear advantages. The reasons for these differences include variations in how studies were designed, which patients they included, and which specific GLP-1 drugs were tested.

The researchers used a framework called GRADE to assess the certainty of evidence for each finding. This framework helps distinguish between findings supported by high-quality research and those based on studies with more limitations. The results indicated that certainty varied substantially depending on which specific outcome researchers were examining.

While GLP-1 drugs show potential as possible add-on therapy for Type 1 diabetes, the current body of research does not yet provide clear enough guidance for broad clinical recommendations. The mix of overlapping studies, inconsistent findings, and variable evidence quality means that more rigorous, independent research is needed.

If you or a loved one has Type 1 diabetes and are curious about GLP-1 drugs, the most appropriate step is to discuss current evidence and individual circumstances with your diabetes care team. They can help determine whether participation in a clinical trial or other research-based approaches might be right for you, and they can monitor any emerging evidence as it develops.

Source: Diabetes, obesity & metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.